Recombinant Technologies

Recombinant Technologies

Revolutionary Alzheimer's Treatment

Recombinant Technologies is developing a revolutionary treatment for Alzheimer's Disease. By designing an injection of a molecule treatment to reduce the plaque buildup that causes dementia, we have successfully improved memory in mice and are ready to move toward human trials.

Security Type
Common Stock
Min Investment
Cheshire, CT
Offering Date
July 14, 2021
Expected Close Date
January 13, 2022
Amount Raised
Security Price


Pazhani Sundaram PhD, President, Chief Executive Officer
Dr. Pazhani Sundaram has a Ph.D. in Biochemistry and Molecular Biology. He is the founder of Recombinant Technologies, a pre-clinical stage biotechnology company []. Dr. Sundaram has strong experience in protein expression technologies, molecular biology, biochemistry, peptidomimetics, and in drug delivery systems. Prior to starting Recombinant Technologies in 1998, he was trained at Yale School of Medicine for about a decade. At Yale, Dr. Sundaram contributed to the research and development of a vaccine to treat the human papillomavirus in a rabbit model. This work formed the basis for Merck in developing the vaccine for HPV 16, which was marketed as 'Gardasil'. Dr. Sundaram's research is acknowledged on Merck's patent for the above vaccine.
Dr. Sundaram's focus for the past 19 years has been to develop a viable drug to treat Alzheimer's Disease. He has been awarded multiple SBIR grants and matching grants to perform this task. He is also an inventor of the patented drug called 'Amytrap' to treat Alzheimer's Disease. Current research focuses on the safety/toxicology assessment of this drug with the support of a recent phase 2 SBIR grant award. Efforts are underway to join forces with investors from multiple platforms to expedite the preclinical development activities. Immediate efforts are focused on developing a device called 'Amytrapper' to trap amyloid from circulation utilizing the proprietary API molecule. This research is also supported by a peer-reviewed grant from NIA.

Research Reports

No reports have been submitted

Become a Reporter

Security Description

Common stock is a security that represents ownership in a corporation.

Key Deal Facts

There are an estimated 5,500,000 people in the U.S. who have Alzheimer’s disease, and we have developed an innovative treatment that addresses the cause of the disease rather than the symptoms. By this treatment strategy, we are addressing a significant unmet medical need and opportunity.
Our patented technology was developed over a decade with the support of $4.5 million in grants and has successfully improved memory in mice in our proof of concept trials.
Our team is comprised of top experts in their fields, including our founder who trained at Yale School of Medicine for about a decade prior to founding this company.